Johnson & Johnson: mixed data for nasal spray for depression

(CercleFinance.com) - Johnson & Johnson's Janssen said that a Phase 3 clinical study on an experimental nasal spray for patients with depression did not demonstrate statistical significance for the primary endpoint.


However, the drugmaker said that results of the primary endpoint and key secondary endpoints favored esketamine nasal spray plus oral antidepressant over the oral antidepressant plus placebo group, supporting a "positive benefit-risk assessment."

Janssen is seeking FDA approval of esketamine for treatment-resistant depression in adults, saying that one-third of patients with major depressive disorder do not respond to existing therapies.

Copyright (c) 2018 CercleFinance.com. All rights reserved.